Skip to main content

Catalyst Calendar

Scope

Thu, Sep 24, 2026

1 updates
RGNX
7:17 PM

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no additional treatment for diabetic retinopathy No IOI observed with short-course prophylactic topical

Presentation / Abstract • Phase 2Retina Society presentation Thu, Sep 24, 2026, EDTregenxbio.com

Tue, Sep 8, 2026

1 updates
RGNX
7:05 AM

REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Sept. 8, 2026 / PRNewswire / -- REGENXBIO Inc. ( Nasdaq: RGNX) today announced it will participate in the following investor conferences: Baird 2026 Global Healthcare Conference Fireside Chat: Tuesday, September 15 at 8:30 a.m. ET Location: New York, NY Morgan Stanley 24th Annual

regenxbio.com

Tue, Aug 25, 2026

1 updates
RGNX
7:05 AM

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across its late-stage pipeline of potential first-and best-in-class gene therapies, Mr.

regenxbio.com

Mon, Aug 24, 2026

1 updates
RGNX
7:05 AM

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

ROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome. The U.S.

regenxbio.com

Thu, Aug 6, 2026

1 updates
RGNX
7:05 AM

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027 Long-term surabgene lomparvovec (sura-vec, ABBV-RGX-314) data highlight durable safety and efficacy profile ahead of key catalyst Topline data from pivotal

Presentation / Abstract • Phase 1/2ASRS presentation Wed, Jul 1, 2026regenxbio.com

Mon, Aug 3, 2026

1 updates

Sat, Jul 18, 2026

1 updates
RGNX
2:55 PM

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies: Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec; no drug-related

Presentation / Abstract • Phase 1/2ASRS presentation Sat, Jul 18, 2026, 2:55 PM EDTregenxbio.com

Fri, Jul 17, 2026

1 updates

Thu, Jul 16, 2026

1 updates
RGNX
4:26 PM

REGENXBIO Announces Proposed Public Offering of Common Stock

ROCKVILLE, Md., July 16, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it intends to offer and sell, subject to market conditions, $100 million of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be

regenxbio.com